AKT1 and neoplasm: Mounting evidence suggests that phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway (PAM) is commonly altered in TNBC that drives tumor progression and therapy resistance (3–5).